Altimmune wins $120M BARDA contract to advance nasal spray anthrax vaccine

A photomicrograph of Bacillus anthracis bacteria--Courtesy of CDC

Gaithersburg, MD’s Altimmune has secured a sizable contract with BARDA to further develop its nasal spray anthrax vaccine candidate, building on an existing collaboration as the biotech prepares to move into clinical trials.

Potentially worth $120.2 million, the deal will pave the way for Altimmune to test its NasoShield in Phase I with a $14.3 million tranche. Total options for the 5-year deal amount to $105.9 million, possibly covering Phase Ib and II tests plus other manufacturing and regulatory efforts for a vaccine that’s previously been supported by BARDA.

In a head-to-head animal study, Altimmune said its candidate provided protection from anthrax infection with a single dose and proved to be no worse than multiple doses of the only approved anthrax vaccine, BioThrax, made by Rockville, MD’s Emergent BioSolutions.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Though Emergent’s existing anthrax vaccine is stockpiled to protect against attacks, side effects and dosing schedule concerns have created a desire for a better product. To that end, last March BARDA inked a $31 million development agreement to test NuThrax--which is heat-stable and only needs two doses--in Phase III. The NIH and Department of Defense previously supported Phase I and Phase II development for the vaccine.

Altimmune’s contract comes just weeks after Emergent BioSolutions indicated it might reduce its headcount in Lansing, MI, where it produces BioThrax. The company’s current supply contract expires at the end of September and a new deal is under negotiation, a spokesperson told the Lansing State Journal. It’s additionally awaiting FDA approval to produce BioThrax at a plant that needs fewer workers.

Also working to advance an anthrax vaccine candidate is San Diego’s Pfenex, which secured a $143.5 million BARDA deal last August to develop Px563L. That collaboration will initially fund a Phase Ia study with options for further studies and work on manufacturing processes.

- here's the release

Related Articles:
Sole provider of anthrax vaccine in U.S. may cut jobs at Michigan plant
Pfenex enters anthrax vaccines realm with $143.5M BARDA contract
Emergent BioSolutions nabs government funds to test new-and-improved anthrax vaccine

Read more on

Suggested Articles

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

Rather than "we did the best we could," Vas Narasimhan, during an internal call with managers, said Novartis could have handled the Zolgensma crisis…